BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23395317)

  • 1. The role of hepatocyte-specific contrast agents in hepatobiliary magnetic resonance imaging.
    Burke C; Alexander Grant L; Goh V; Griffin N
    Semin Ultrasound CT MR; 2013 Feb; 34(1):44-53. PubMed ID: 23395317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatobiliary-specific MR contrast agents: role in imaging the liver and biliary tree.
    Seale MK; Catalano OA; Saini S; Hahn PF; Sahani DV
    Radiographics; 2009 Oct; 29(6):1725-48. PubMed ID: 19959518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New contrast agents for imaging the liver.
    Helmberger T; Semelka RC
    Magn Reson Imaging Clin N Am; 2001 Nov; 9(4):745-66, vi. PubMed ID: 11694436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Magnetic resonance tomography of the hepatobiliary system: indications, limitations and outlook].
    Vogl TJ; Hammerstingl R; Schnell B; Eibl-Eibesfeldt B; Peqios W; Lissner J
    Bildgebung; 1992 Dec; 59(4):195-9. PubMed ID: 1292771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatocyte-specific magnetic resonance imaging contrast agents.
    Fidler J; Hough D
    Hepatology; 2011 Feb; 53(2):678-82. PubMed ID: 21274888
    [No Abstract]   [Full Text] [Related]  

  • 6. [Status and development of new clinical contrast media for MR diagnosis of liver diseases].
    Rummeny EJ; Peters PE
    Radiologe; 1992 May; 32(5):225-31. PubMed ID: 1635982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatobiliary enhancement with Gd-EOB-DTPA: comparison of spin-echo and STIR imaging for detection of experimental liver metastases.
    Mühler A; Clément O; Vexler V; Berthezène Y; Rosenau W; Brasch RC
    Radiology; 1992 Jul; 184(1):207-13. PubMed ID: 1609081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mangafodipir trisodium-enhanced MRI for the detection and characterization of focal hepatic lesions: is delayed imaging useful?
    Chung JJ; Kim MJ; Kim KW
    J Magn Reson Imaging; 2006 May; 23(5):706-11. PubMed ID: 16565954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Magnetic resonance imaging of focal liver lesions: approach to imaging diagnosis.
    Fowler KJ; Brown JJ; Narra VR
    Hepatology; 2011 Dec; 54(6):2227-37. PubMed ID: 21932400
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced magnetic resonance cholangiography with Gd-BOPTA and Gd-EOB-DTPA in healthy subjects.
    Dahlström N; Persson A; Albiin N; Smedby O; Brismar TB
    Acta Radiol; 2007 May; 48(4):362-8. PubMed ID: 17453513
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver. III: Gadolinium-based hepatobiliary contrast agents (Gd-EOB-DTPA and Gd-BOPTA/Dimeg).
    Giovagnoni A; Paci E
    Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):61-72. PubMed ID: 8673717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic challenges and pitfalls in MR imaging with hepatocyte-specific contrast agents.
    Goodwin MD; Dobson JE; Sirlin CB; Lim BG; Stella DL
    Radiographics; 2011 Oct; 31(6):1547-68. PubMed ID: 21997981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primovist, Eovist: what to expect?
    Van Beers BE; Pastor CM; Hussain HK
    J Hepatol; 2012 Aug; 57(2):421-9. PubMed ID: 22504332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Magnetic resonance imaging of the liver: what kind of contrast agents?].
    De Gaspari A; De Cobelli F; Del Maschio A
    Radiol Med; 2001 Sep; 102(3):109-21. PubMed ID: 11677451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biliary MR imaging with Gd-EOB-DTPA and its clinical applications.
    Lee NK; Kim S; Lee JW; Lee SH; Kang DH; Kim GH; Seo HI
    Radiographics; 2009 Oct; 29(6):1707-24. PubMed ID: 19959517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gadoxetic acid-enhanced hepatobiliary phase MR imaging: cellular insight.
    Pastor CM
    Radiology; 2010 Nov; 257(2):589. PubMed ID: 20959554
    [No Abstract]   [Full Text] [Related]  

  • 17. MRI findings of hepatocellular carcinoma.
    Wiwanitkit V
    Magn Reson Imaging; 2011 Feb; 29(2):303. PubMed ID: 21129874
    [No Abstract]   [Full Text] [Related]  

  • 18. MRI findings of rapidly progressive hepatocellular carcinoma.
    Kierans AS; Leonardou P; Hayashi P; Brubaker LM; Elazzazi M; Shaikh F; Semelka RC
    Magn Reson Imaging; 2010 Jul; 28(6):790-6. PubMed ID: 20427139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications.
    Reimer P; Schneider G; Schima W
    Eur Radiol; 2004 Apr; 14(4):559-78. PubMed ID: 14986050
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of focal liver lesions: use of mangafodipir trisodium (MnDPDP)-enhanced MR images.
    Karabacakoğlu A; Adigüzel Y; Karaköse S; Kayaçetin E; Haykir R
    Turk J Gastroenterol; 2006 Sep; 17(3):164-71. PubMed ID: 16941248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.